The COVID-19 treatment trials that ‘learn as they go’

In the event of an outbreak of an infectious disease, such as the current COVID-19 pandemic, we often know very little, yet are required to act very fast. In this article, Dr Robert Mahar and Dr David Price from the Centre for Epidemiology and Biostatistics, along with A/Prof Steven Tong from the Doherty Institute for Infection and Immunity, explain how innovative approaches to clinical trials for COVID-19 treatments can enable us to quickly hone in on the most promising treatments, saving time and potentially saving lives.

Read the full original article.

Related People

Dr David Price
Affiliated Investigator
Post-doctoral Biostatistician